Abstract
Bladder cancer is the most common cancer of the urinary system and its treatment has scarcely progressed for nearly 30 years. Advances in checkpoint inhibitor research have seemingly provided a new approach for treatment. However, there have been issues predicting immunotherapeutic biomarkers and identifying new therapeutic targets. We downloaded the gene expression profile and clinical data of 408 cases bladder urinary cancer from the Cancer Genome Atlas (TCGA) portal, and the abundance ratio of immune cells for each sample was obtained via the “Cell Type Identification by Estimating Relative Subsets of RNA Transcripts (CIBERSORT)” algorithm. Then, four survival-related immune cells were obtained via Kaplan-Meier survival analysis, and 933 immune-related genes were obtained via a variance analysis. Enrichment, protein-protein interaction, and co-expression analyses were performed for these genes. Lastly, 4 survival-related immune cells and 24 hub genes were identified, four of which were related to overall survival. More importantly, these immune cells and genes were closely related to the clinical features. These cells and genes may have research value and clinical application in bladder cancer immunotherapy. Our study not only provides cell and gene targets for bladder cancer immunotherapy, but also provides new ideas for researchers to explore the immunotherapy of various tumors.
Introduction
Bladder cancer is the nineth most common malignant neoplasm in the world. It is mainly represented by bladder urothelial carcinoma (BUC), which accounts for >90% of bladder cancer, and smoking is recognized as the most common risk factor (1, 2). The traditional treatments for bladder cancer mainly include surgical resection and chemotherapy, but there is a high recurrence rate, and the 5 year overall survival rate remains at 15–20% (3, 4). Owing to advancements in immuno-oncology and the introduction of checkpoint inhibitors in clinical practice for many cancers in recent years, there is hope for progress in the treatment of bladder cancer (5). Bacillus Calmette–Guérin is considered the earliest immunotherapeutic drug applied to bladder cancer, but its clinical application is limited due to low efficiency and high toxicity. Immunological checkpoint inhibitors are immunotherapeutic drugs that have emerged in recent years, and many clinical trials on these drugs are proceeding (6). A study from the Cancer Genome Atlas (TCGA) showed that bladder cancer is a disease with a large number of different genetic mutations, and may be sensitive to immunotherapy due to the high number of identifiable antigens (7). This finding suggests that immunotherapy may be beneficial in the treatment of bladder cancer. Many clinical trials of bladder cancer immunotherapy are currently in progress, but there are no results on efficacy, particularly compared to traditional cisplatin-based chemotherapy. Moreover, no approval has been given to any form of bladder cancer immunotherapy according to the Food and Drug Administration (6). The beneficiaries of immunotherapy are still limited to small-scale populations, and tumor-induced immune escape is a ubiquitous phenomenon. Many problems remain to be solved in BUC immunotherapy, especially in the field of predicting immunotherapeutic biomarkers and identifying new effective therapeutic targets.
Studies on the tumor microenvironment have been increasingly published in the field of cancer immunotherapy (8). The tumor microenvironment is the surrounding environment in which tumor cells reside, and consists of immune cells, mesenchymal cells, endothelial cells, inflammatory mediators, and extracellular molecules (9, 10). It is a powerful protective net for tumor cells formed in the fight between the tumor and the immune system, and it is also the premise and guarantee of tumor immune escape. Immune components in the tumor microenvironment have essential effects on gene expression by tumor tissues and the clinical outcome (11–13).
Cancer immunotherapy mainly works with some important proteins to enhance function or restore immune cells in the tumor microenvironment. Thus, we first explored survival-related immune cells in BUC, and then explored genes that are critical to the level of immune cell infiltration. In this study, the RNA-sequencing (RNA-Seq) gene expression profile and clinical data of 408 patients with BUC were downloaded from the TCGA database, and data extraction and analysis were performed with R software. A total of four survival-related immune cells and 24 hub genes were identified, four of which were related to survival. We validated the immune correlation through the online website “Tumor Immune Estimation Resource (TIMER).” Our study provides ideas and clues to BUC immunotherapy, and the cells and genes that were identified could be considered biomarkers for prognosis or targets for BUC therapy. Furthermore, this study also provides a new approach for immunotherapy researchers to explore immunotherapeutic cells and gene targets for the first time.
Materials and Methods
Data Source and Pre-processing
The RNA-Seq gene expression profiles of patients with BUC, including the FPKM and count format, were downloaded from the TCGA database using the gdc-client download tool. Clinical data, such as gender, age, tumor grade, clinical stage, and survival time, were also downloaded from the TCGA portal. Then, R software (R Foundation for Statistical Computing, Vienna, Austria) was used for data extraction and sorting to obtain the gene expression matrices and clinical data. Subsequent analyses were conducted, and all analytical processes are shown in Figure 1.
Figure 1
Identifying Survival-Related Immune Cells
CIBERSORT is an analytical tool developed by Newman to provide an estimate of the abundance ratio of member cell types in a mixed cell population using gene expression data (14). We ran CIBERSORT locally in R software (15). The RNA-Seq (FPKM format) of BUC was analyzed to obtain the abundance ratio matrix of 22 immune cells. In total, 218 samples were selected with P ≤ 0.05. Then, a correlation analysis was conducted among the contents of the 22 immune cells in the 218 samples. Next, the Kaplan-Meier analysis for overall survival was proceeded based on the abundance ratio of 22 immune cells whose cut-off level was set at the median value with the aid of R software and the Log-Rank was utilized to test. We identified survival-related immune cells according to the results of the Kaplan-Meier survival analysis.
Clinical Relationship With Survival-Related Immune Cells
The relationship between the abundance ratio of immune cells and tumor grade, clinical stage, stage T, and stage N was analyzed by combining the abundance ratio of immune cells and the clinical features in the 218 samples. Two variates used the independent sample t-test, while more variates used one-way ANOVA test. In this way, we could better understand the relevance of the clinical relationship with survival-related immune cells.
Identifying Immune-Related Genes
According to the grouping in step 2.2 and the survival-related cells identified, we analyzed and obtained the genes related to each immune cell infiltration level. The differentially expressed genes were analyzed with the edgeR R package and the condition that |logFC| > 1.5 and P < 0.05. A Venn calculation and visualization were conducted via the online tool (http://bioinformatics.psb.ugent.be/webtools/Venn/) to obtain unique results for these genes.
Enrichment Analysis of Immune-Related Genes
Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were used to annotate the structure, functions, and pathways of the genes. The DAVID website (https://david.ncifcrf.gov/) is one of the most authoritative enrichment tools (16). We used DAVID to analyse immune-related genes in the GO and KEGG pathways. Counts ≥ 4 and P < 0.05 were set as the enrichment cut-offs to screen meaningful enrichment results. Counts indicate the number of genes enriched in one GO/KEGG term. P-value is the judgment of significance of enrichment results. The enrichment results were visualized via the ggplot2 R package.
Protein-Protein Interaction Network Construction, Hub Genes, and Modules Analysis
The 933 immune-related genes were imported into the STRING database (https://string-db.org/), a web tool used to explore protein-protein interactions, and the combined-score was set to ≥ 0.4 (17). The interaction network consisted of 829 nodes and 4,850 edges. This network was reconstructed via Cytoscape software and analyzed via the “molecular complex detection (MCODE)” plugin. In total, 29 modules were analyzed, including 24 seed genes, which were named hub genes. Then, we analyzed and obtained the 50 highest related genes to the 24 hub genes and the co-expression network of these genes via the cBioPortal online website (http://www.cbioportal.org/) (18, 19). For the co-expression analysis, the “TCGA provisional” dataset was selected and set as 7.5 in “Filter Neighbors by Alteration (%).” Lastly, we selected two modules with a gene number > 50 from MCODE and the co-expression network to perform GO/KEGG analysis via DAVID. The enrichment cut-off value was set to an adj. P < 0.05 and count ≥ 5.
Relationship Between Clinical Characteristics and Hub Genes
The relationship between hub genes and clinical characteristics was analyzed and visualized by the “Weighted Correlation Network analysis (WGCNA)” package in R. The 218 patients were grouped and analyzed for overall survival according to the expression level of the 24 hub genes, as for the Kaplan-Meier survival analysis of the immune cells.
Validation of the Immune Correlation
For validating the immune correlation of 24 hub genes, we employed the method of Pearson correlation analysis to analyse the correlation between these hub genes and 22 immune cells, which have got via the CIBERSORT in section identifying survival-related immune cells. The correlation index r and corresponding p-value are visualized via canvasXpress R package. TIMER (https://cistrome.shinyapps.io/timer/) is a comprehensive resource to systematically analyse immune infiltrates across diverse cancer types. The abundances of six immune cells (B cells, CD4+ T cells, CD8+ T cells, neutrophils, macrophages, and dendritic cells [DCs]) were estimated by a special statistical method, which was validated using a pathological estimate and the results are reliable (20). Survival-related hub genes were also validated for immune correlation via TIMER.
Results
Data Source and Pre-processing
The 408 cases of BUC data were downloaded and extracted into three matrices, including the RNA-Seq (FPKM and counts format) and clinical data. The subsequent analytical pre-processing for the study is shown in Figure 1.
Identifying Survival-Related Immune Cells
The abundance ratio of 22 immune cells in the 218 samples and their correlations were analyzed and are shown in Figures 2A,B. T cell CD4 memory activated and T cell CD8 contents were significantly correlated, while T cell CD4 memory resting was negatively correlated with T cell CD8 and T cell CD4 memory activated. Additionally, we analyzed the relationship between the abundance ratio of the 22 types of immune cells and overall survival via Kaplan-Meier analysis. The results in Figures 2C–F show that the abundance ratio of the four immune cells was related to survival, including T cell CD4 memory activated, T cell CD8, T cell CD4 memory resting, and natural killer (NK) cell resting.
Figure 2
Clinical Relationship With Survival-Related Immune Cells
A correlation analysis was carried out between the contents of the four survival-related immune cells and the clinical characteristics (including stage T, stage N, clinical stage, and tumor grade) to determine the effect of the immune cell abundance ratio on BUC clinical features. As shown in Figure 3, the abundance ratio of T cell CD8, NK cell resting, and T cell CD4 memory resting decreased with the increase of stage T/stage N/clinical stage, while the abundance ratio of T cell CD4 memory activated increased in an opposite manner. Because there were only three cases of low-grade BUC, the relationship between BUC grade and survival-related immune cells was unclear.
Figure 3
Identifying Immune-Related Genes
We analyzed the genes related to the levels of the four survival-related immune cells and found that 514 genes were related to T cell CD8, 510 to NK cell resting, 560 to T cell CD4 memory resting, and 534 to T cell CD4 memory activated. Volcano plots were used to show the results in Figures 4A–D. The Venn map analysis shown in Figure 4E revealed 933 genes totally related to immune cells infiltration.
Figure 4
Enrichment Analysis of Immune-Related Genes
To investigate the biological classifications of immune-related genes, a GO/KEGG enrichment analysis was performed using the DAVID website, and the top 12 enrichment results for each term are plotted in Figure 5. GO analysis results showed that changes in the biological process (Figure 5A) of immune-related genes were significantly enriched in keratinization, peptide cross-linking, regulation of ion transmembrane transport, ion transmembrane transport, cell-cell signaling, etc. Changes in the molecular function (Figure 5B) were mainly enriched in keratin filament, extracellular region, intermediate filament, anchored component of membrane, Golgi lumen, acetylcholine-gated channel complex, etc. Changes in cellular component (Figure 5C) were mainly enriched in sequence-specific DNA binding, serine-type endopeptidase inhibitor activity, neuropeptide Y receptor activity, arachidonic acid epoxygenase activity, serotonin-activated cation-selective channel activity, etc. KEGG pathway analysis (Figure 5D) demonstrated that Metabolism of xenobiotics by cytochrome P450, Chemical carcinogenesis, Tyrosine metabolism, PPAR signaling pathway, etc. In brief, 933 immune-related genes were mainly involved in the transmission of various signaling pathways, as well as transportation and metabolism of nutrients.
Figure 5
Protein-Protein Interaction Network Construction, Hub Genes, and Module Analysis
To explore the interrelation of immune-related genes and obtain hub genes, we made a PPI and module analysis, and obtained 24 hub genes, 2 modules with genes >50, 50 co-expression genes, and the co-expression network. The information of the 24 hub genes is shown in Table 1, including the full gene names and primary functions. The two modules with genes >50 and the co-expression networks are shown in Figures 6A–C, respectively. According to the results of the enrichment analysis for three modules shown in Table 2, module 1 genes were mainly related to protein transport and metabolism, module 2 genes were mainly related to the composition of keratin and intermediate filaments, and the co-expression network genes were mainly related to various signaling pathways associated with cancer. Of the three modules, the most interesting and important one is the co-expression network. It is involved in many pathways related to cancer and immunity, such as G-protein coupled receptor signaling pathway, Wnt signaling pathway, regulation of phosphatidylinositol 3-kinase signaling, PI3K-Akt signaling pathway, ErbB signaling pathway, etc.
Table 1
| No. | Gene | Full name | Function |
|---|---|---|---|
| 1 | KRTAP19-6 | Keratin associated protein 19-6 | Developmental biology and keratinization |
| 2 | CHRM1 | Cholinergic receptor muscarinic 1 | Monoamine GPCRs and peptide ligand-binding receptors |
| 3 | AGTR2 | Angiotensin II receptor type 2 | Agents acting on the renin-angiotensin system pathway, pharmacodynamics and peptide ligand-binding receptors |
| 4 | SPRR2F | Small proline rich protein 2F | Cross-linked envelope protein of keratinocytes |
| 5 | GPR32 | G protein-coupled receptor 32 | Signaling by GPCR and G alpha (s) signaling events |
| 6 | UGT2B15 | UDP glucuronosyltransferase family 2 member B15 | Carbohydrate binding and glucuronosyltransferase activity |
| 7 | PSD2 | Pleckstrin and Sec7 domain containing 2 | Phospholipid binding and ARF guanyl-nucleotide exchange factor activity |
| 8 | MPPED1 | Metallophosphoesterase domain containing 1 | Hydrolase activity |
| 9 | STMN2 | Stathmin 2 | calcium-dependent protein binding and tubulin binding |
| 10 | CST4 | Cystatin S | cysteine-type endopeptidase inhibitor activity |
| 11 | DGKK | Diacylglycerol kinase kappa | Glycerolipid metabolism and Signaling by GPCR |
| 12 | DMRTC2 | DMRT like family C2 | DNA-binding transcription factor activity and sequence-specific DNA binding |
| 13 | KRTAP2-3 | Keratin associated protein 2–3 | Developmental biology and keratinization |
| 14 | CSH1 | Chorionic somatomammotropin hormone 1 | Peptide ligand-binding receptors and Growth hormone receptor signaling |
| 15 | DSG4 | Desmoglein 4 | Developmental biology and keratinization |
| 16 | LIN28A | Lin-28 homolog A | Developmental biology and Wnt/hedgehog/notch |
| 17 | NKD1 | NKD inhibitor of Wnt signaling pathway 1 | Wnt/hedgehog/notch and wnt signaling pathway and pluripotency |
| 18 | KLK2 | Kallikrein related peptidase 2 | Agents acting on the renin-angiotensin system pathway, pharmacodynamics and signaling by Rho GTPases |
| 19 | FOXN4 | Forkhead box N4 | DNA-binding transcription factor activity and chromatin binding |
| 20 | UNC93A | Unc-93 homolog A | Toll-like receptor binding |
| 21 | LUZP1 | Leucine zipper protein 1 | chromosome 1p36 deletion syndrome |
| 22 | OTOG | Otogelin | Structural molecule activity and alpha-L-arabinofuranosidase activity |
| 23 | CDH7 | Cadherin 7 | ERK signaling and nanog in mammalian ESC pluripotency |
| 24 | TRIM51 | Tripartite motif-containing 51 | No data available |
Functional roles of the 24 hub genes.
Figure 6
Table 2
| Modules | Description | P.adjust | Count | |
|---|---|---|---|---|
| Modules 1 | BP terms | O-glycan processing | 1.95E-04 | 7 |
| Cellular protein metabolic process | 6.24E-04 | 8 | ||
| Respiratory gaseous exchange | 0.0141 | 5 | ||
| CC terms | Lamellar body | 1.47E-05 | 5 | |
| Clathrin-coated endocytic vesicle | 2.81E-04 | 5 | ||
| Extracellular region | 0.00142 | 21 | ||
| Golgi lumen | 0.001888 | 7 | ||
| Extracellular space | 0.001995 | 19 | ||
| Modules 2 | CC terms | Intermediate filament | 1.84E-60 | 35 |
| Keratin filament | 2.16E-40 | 26 | ||
| MF terms | Structural molecule activity | 1.61E-30 | 23 | |
| Co-expression | BP terms | Signal transduction | 1.79E-06 | 22 |
| G-protein coupled receptor signaling pathway | 5.32E-05 | 18 | ||
| Platelet activation | 4.55E-04 | 8 | ||
| Wnt signaling pathway | 9.23E-04 | 9 | ||
| Positive regulation of ERK1 and ERK2 cascade | 0.007655 | 8 | ||
| Regulation of phosphatidylinositol 3-kinase signaling | 0.01949 | 6 | ||
| Positive regulation of cytosolic calcium ion concentration | 0.020014 | 7 | ||
| CC terms | Plasma membrane | 3.47E-04 | 36 | |
| MF terms | Protein kinase activity | 0.016453 | 10 | |
| KEGG pathway | Chemokine signaling pathway | 6.32E-06 | 13 | |
| Adherens junction | 3.90E-05 | 9 | ||
| Wnt signaling pathway | 6.02E-04 | 10 | ||
| Cholinergic synapse | 0.001299 | 9 | ||
| Glutamatergic synapse | 0.001592 | 9 | ||
| GABAergic synapse | 0.002653 | 8 | ||
| Pathways in cancer | 0.003451 | 14 | ||
| Morphine addiction | 0.004209 | 8 | ||
| Circadian entrainment | 0.005621 | 8 | ||
| Retrograde endocannabinoid signaling | 0.008465 | 8 | ||
| Serotonergic synapse | 0.015818 | 8 | ||
| PI3K-Akt signaling pathway | 0.03281 | 12 | ||
| Dopaminergic synapse | 0.040082 | 8 | ||
| ErbB signaling pathway | 0.041677 | 7 |
GO and KEGG pathway enrichment analysis of the top 2 modules and co-expression network.
Relationship Between Clinical Characteristics and Hub Genes
The correlation analysis results of the clinical characteristics for the 24 hub genes are shown in Figure 7A. CDH7 was positively correlated with stage N, while CST4 was negatively correlated with stage T. The relationship between other hub genes and clinical characteristics can be easily found in the figure. The Kaplan-Meier survival analysis (Figures 7B–E) shows that four of the 24 hub genes strongly associated with clinical outcomes were CDH7, LUZP1, PSD2, and UGT2B15.
Figure 7
Validation of the Immune Correlation
The 24 hub genes are potential immunotherapeutic targets, and their relationship and interaction with immune cells are of great value for farther immune-related research. The correlation analysis results between the 24 hub genes and 22 immune cells are shown in Figure 8A. TIMER was used to validate the correlation between the four survival-related genes and the level of immune cell infiltration, and the results are shown in Figure 8B. Part of hub genes, including four survival-related genes, were significantly correlated with some certain immune cell infiltrate.
Figure 8
Discussion
Bladder cancer is the most common tumor of the urinary system, and its treatment progress has been slow. In recent years, the discovery of immune checkpoints has pushed cancer immunotherapy to a new level, achieving specific blockade of immunosuppressive effects and enhancing the anti-tumor immune response. Accumulating clinical data show that cancer immunotherapy is a key step in clinical cancer management (10). The purpose of our study was to screen and identify cells and genes closely related to immune infiltration and clinical outcomes in the BUC microenvironment. Our study not only identified cell and gene targets for BUC immunotherapy, but also proposes a new research idea for immunotherapy of other tumors.
In this study, four kinds of immune cells were related to the survival of patients with bladder cancer, including T cell CD8, T cell CD4 memory resting, T cell CD4 activated, and NK cell resting. CD8+ T cells are a hot spot in cancer research. Programmed death-1 (PD-1) on the surface of CD8+ T cells binds programmed death-ligand 1 (PD-L1) produced by tumor tissue, resulting in a limited host immune response. PD-L1 inhibitors increase the infiltration level of CD8+ T cells, which is an effective anti-tumor immune response (21). CD4+ memory T cells play an essential role in tumourigenesis and enlargement (22). CD4+ central memory T (TCM) cells maintain immune memory and exert immunoprotective effects during tumor metastasis (23, 24). CD4+ effector memory T (TEM) cells express adhesion molecules and chemokine receptors, which perform rapid functions (25). Both play a vital role in anti-tumor immunity, while TCM cells have more advantages than TEM cells (26). In the peripheral blood of patients with advanced cancer, the proportion of TCM cells decreases and TEM cells increases, presenting the typical T cell depletion status (27). In that study, patients with high T cell CD4 memory activated had shorter overall survival, while patients with high T cell CD4 memory resting had longer overall survival. This is consistent with the T cell depletion status theory. NK cells are an important part of the innate immune system, performing the function of memory antigen-specific immunity (28, 29). NK cells directly kill target cells, effectively remove diseased cells, and conduct immune surveillance. Some studies have shown that exercise-dependent mobilization of NK cells plays a crucial role in exercise-mediated protection against cancer (30–32). In summary, the four survival-related cells identified in this study are most likely to play an important role in immune infiltration as well as BUC immunotherapy, confirming that the analysis of immune-related genes based on the cells is credible.
The enrichment analysis of immune-related and co-expressed genes showed that these genes are mainly correlated with the transportation and metabolism of various nutrients (proteins, lipid, sugars, water, and ions) and various signaling pathways. By searching the signaling pathways enriched on the KEGG website (https://www.genome.jp/kegg/), we found that the PPAR signaling pathway, the epoxygenase P450 pathway, and the PI3K-Akt signaling pathway are involved in substance metabolism. The PI3K-Akt, Wnt, chemokine, and ErbB signaling pathways, as well as circadian rhythms and chemical carcinogenesis, are mainly associated with tumor cell metastasis, differentiation, survival, angiogenesis, and biological clocks. Metabolic change is an important feature of tumors. To meet the energy and biosynthetic demands of rapid proliferation, tumor cells use aerobic glycolysis for rapid energy supply (33). Different immune cell subsets also use different nutrients as an energy supply. Activated T cells, effector T (Teff) cells, including CD8+ T, CD4+ Th1, CD4+ Th2, and Th17, activated DCs, and activated M1 macrophages all use aerobic glycolysis, while the immunosuppressive cell subsets, such as regulatory T (Treg) cells, myeloid-derived suppressor cells, DC resting, and naive T cells use fatty acid oxidation to supply energy (34, 35). Thus, there is a competition between tumor cells and immune cells for energy. It has been shown that the severe nutrient deprivation in the tumor microenvironment allows Treg cells to use lactate as an energy substrate, while inhibiting lactate metabolism reduces Treg cell content (36). Similarly, promoting tryptophan degradation inhibits Teff cell function (37). These results indicate that the metabolic pattern of tumor tissue is related to immune cells, which can change the metabolism of specific substances to achieve different levels of immune cell infiltration and realize the treatment of tumors. Based on this evidence, we predict that these energy metabolism-related pathways act as an important bridge between immune infiltration and energy metabolism of BUC and are worthy of further study.
Of the enrichment analysis results, the PI3K-Akt signaling pathway is the clearest and important one to regulate immune environment. The general consensus is that the PI3K-Akt signaling pathway has the capacity to affect immune cell effector function and to regulate the immune-intrinsic features (38). Within the tumor microenvironment, a variety of immune cells co-exist in and interact with each other, and the activation of most immune cells are affected by the PI3K-AKT signaling pathway (39, 40). AKT can balance the terminal differentiation and production of memory CD8+T cells via regulating TCR, IL-2 receptor, and IL-12 receptor, etc. (41). Peng (42) and Abu-Eid et al. (43) found that PI3K inhibitor /AKT inhibitor could significantly increase the infiltration of CD8+T cells in tumor tissues and significantly prolong survival time. Meanwhile, AKT inhibitors can even effectively enhance the differentiation of other memory T cells in tumor tissues (44, 45). Abu-Eid et al. (43) found that PI3K-Akt pathway inhibitors selectively inhibit Tregs with minimal effect on conventional T cells to enhance the antitumour immune response. Okkenhaug et al. (46) proved that the PI3K-AKT-m TOR signaling pathway contributes to the development and activity of lymphocytes. Additional immune microenvironment features, such as the expression of immune checkpoint PD-L1 and inflammation within the tumor, are also modulated by the PI3K-AKT pathway (38). Other signaling pathways, such as Wnt, chemokine, chemical carcinogenesis, etc. are also more or less related to immunity.
Finally, a total of 24 hub genes were identified, four of which were related to survival, namely CDH7, LUZP1, PSD2, and UGT2B15. Previous studies have failed to investigate the relationship between these four genes and immunity, and only a few studies have shown that these genes are involved in the development of certain tumors. CDH7 is a typical adhesion molecule, and some studies have shown that CDH7 is a melanoma inhibitory protein binding partner that affects the migration of malignant melanoma cells (47–49). LUZP1 is a basic component of many proteins as well as a significant component of the group of membrane proteins on the surface of NK cells. Upregulation of LUZP1 is associated with a poor prognosis of liver cancer (50). UGT2B15 is associated with gastric cancer, breast cancer, and prostate cancer. UGT2B15 may upregulate FOXA1 and activate the hippocampal-yap signaling pathway to promote the development of gastric cancer (51). In breast cancer, UGT2B15 is regulated by sex hormone signaling in estrogen receptor-positive breast cancer (52). In human prostate cancer cells, androgen glucuronidation catalyzed by glucuronyltransferase is one of the main pathways to inactivate androgens, and high androgen expression is essential in the pathogenesis of prostate cancer (53).
In conclusion, four survival-related immune cells and 24 hub genes were identified, and four of these genes were shown to be related to overall survival in patients with BUC. These cells and genes can be considered biomarkers for prognosis, or as markers for bladder cancer therapy, which can be a focus of immunotherapy for bladder cancer. However, the evidence of this study remains indirect, and from bioinformatics, as with other similar studies. Through further research on these cells and genes, a new understanding of the potential relationship between the tumor microenvironment and BUC immunotherapy as well as prognosis can be achieved.
Statements
Data availability statement
Publicly available datasets were analyzed in this study, these can be found in The Cancer Genome Atlas (https://portal.gdc.cancer.gov/).
Author contributions
The study conception and design were performed by JC and JT. Material preparation, data collection, and analysis were performed by JC, XY, JL, HW, PL, and ZY. The first draft of the manuscript was written by JC, JL, and ZD. All authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.
Funding
This work was supported by the Fundamental Research Funds for the Central Universities (Project number: 561219007), Doctoral Research Foundation of Lanzhou University Second Hospital (Project number: ynbskyjj2015-2-7), Cuiying Scientific and Technological Innovation Program of Lanzhou University Second Hospital (Project number: CY2017-BJ16), Cuiying Graduate Supervisor Applicant Training Program of Lanzhou University Second Hospital (Project number: 201704), Industry Planning Project of Health Department of Gansu Province (Project number: GWGL2013-30), and Science and Technology Project of Chengguan District, Lanzhou City, Gansu Province Science and Technology Bureau (Project number: 2017KJGG0052).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1.
AntoniSFerlayJSoerjomataramIZnaorAJemalABrayF. Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol. (2017) 71:96–108. 10.1016/j.eururo.2016.06.010
2.
FerlayJSoerjomataramIDikshitREserSMathersCRebeloMet al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. (2015) 136: E359–86. 10.1002/ijc.29210
3.
Bladder cancer: diagnosis and management of bladder cancer: (c) NICE (2015) Bladder cancer: diagnosis and management of bladder cancer. BJU Int. (2017) 120:755–65. 10.1111/bju.14045
4.
AggenDHDrakeCG. Biomarkers for immunotherapy in bladder cancer: a moving target. J Immunother Cancer. (2017) 5:94. 10.1186/s40425-017-0299-1
5.
BellmuntJOrsolaALeowJJWiegelTDe SantisMHorwichA. Bladder cancer: ESMO practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. (2014) 25(Suppl. 3):iii40–8. 10.1093/annonc/mdu223
6.
HindyJRSouaidTKourieHRKattanJ. Targeted therapies in urothelial bladder cancer: a disappointing past preceding a bright future?Future Oncol. (2019) 15:1505–24. 10.2217/fon-2018-0459
7.
WeinsteinJAkbaniRBroomBWangWVerhaakRMcConkeyDet al. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. (2014) 507:315–22. 10.1038/nature12965
8.
FidlerIJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer. (2003) 3:453–8. 10.1038/nrc1098
9.
HanahanDCoussensLM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. (2012) 21:309–22. 10.1016/j.ccr.2012.02.022
10.
ChenDSMellmanI. Oncology meets immunology: the cancer-immunity cycle. Immunity. (2013) 39:1–10. 10.1016/j.immuni.2013.07.012
11.
SenbabaogluYGejmanRSWinerAGLiuMVan AllenEMde VelascoGet al. Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. Genome Biol. (2016) 17:231. 10.1186/s13059-016-1092-z
12.
YoshiharaKShahmoradgoliMMartinezEVegesnaRKimHTorres-GarciaWet al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. (2013) 4:2612. 10.1038/ncomms3612
13.
CooperLAGutmanDAChisolmCAppinCKongJRongYet al. The tumor microenvironment strongly impacts master transcriptional regulators and gene expression class of glioblastoma. Am J Pathol. (2012) 180:2108–19. 10.1016/j.ajpath.2012.01.040
14.
NewmanAMLiuCLGreenMRGentlesAJFengWXuYet al. Robust enumeration of cell subsets from tissue expression profiles. Nat Method. (2015) 12:453–7. 10.1038/nmeth.3337
15.
ChenBKhodadoustMSLiuCLNewmanAMAlizadehAA. Profiling tumor infiltrating immune cells with CIBERSORT. Methods Mol Biol. (2018) 1711:243–59. 10.1007/978-1-4939-7493-1_12
16.
HuangDWShermanBTTanQKirJLiuDBryantDet al. DAVID bioinformatics resources: expanded annotation database and novel algorithms to better extract biology from large gene lists. Nucleic Acids Res. (2007) 35:W169–75. 10.1093/nar/gkm415
17.
SzklarczykDMorrisJHCookHKuhnMWyderSSimonovicMet al. The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res. (2017) 45:D362–8. 10.1093/nar/gkw937
18.
GaoJAksoyBADogrusozUDresdnerGGrossBSumerSOet al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. (2013) 6:pl1. 10.1126/scisignal.2004088
19.
CeramiEGaoJDogrusozUGrossBESumerSOAksoyBAet al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. (2012) 2:401–4. 10.1158/2159-8290.CD-12-0095
20.
LiTFanJWangBTraughNChenQLiuJSet al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. (2017) 77:e108–10. 10.1158/0008-5472.CAN-17-0307
21.
TumehPCHarviewCLYearleyJHShintakuIPTaylorEJRobertLet al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. (2014) 515:568–71. 10.1038/nature13954
22.
SallustoFLenigDForsterRLippMLanzavecchiaA. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. (1999) 401:708–12. 10.1038/44385
23.
LudewigBOehenSBarchiesiFSchwendenerRAHengartnerHZinkernagelRM. Protective antiviral cytotoxic T cell memory is most efficiently maintained by restimulation via dendritic cells. J Immunol. (1999) 163:1839–44.
24.
WherryEJTeichgraberVBeckerTCMasopustDKaechSMAntiaRet al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol. (2003) 4:225–34. 10.1038/ni889
25.
van PanhuysNPerretRProutMRoncheseFLe GrosG. Effector lymphoid tissue and its crucial role in protective immunity. Trends Immunol. (2005) 26:242–7. 10.1016/j.it.2005.03.005
26.
KlebanoffCAGattinoniLTorabi-PariziPKerstannKCardonesARFinkelsteinSEet al. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci USA. (2005) 102:9571–6. 10.1073/pnas.0503726102
27.
KlebanoffCAGattinoniLRestifoNP. CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol Rev. (2006) 211:214–24. 10.1111/j.0105-2896.2006.00391.x
28.
VivierERauletDHMorettaACaligiuriMAZitvogelLLanierLLet al. Innate or adaptive immunity? The example of natural killer cells. Science. (2011) 331:44–9. 10.1126/science.1198687
29.
SunJCBeilkeJNLanierLL. Adaptive immune features of natural killer cells. Nature. (2009) 457:557–61. 10.1038/nature07665
30.
MorvanMGLanierLL. NK cells and cancer: you can teach innate cells new tricks. Nat Rev Cancer. (2016) 16:7–19. 10.1038/nrc.2015.5
31.
LongEOKimHSLiuDPetersonMERajagopalanS. Controlling natural killer cell responses: integration of signals for activation and inhibition. Ann Rev Immunol. (2013) 31:227–58. 10.1146/annurev-immunol-020711-075005
32.
IdornMHojmanP. Exercise-dependent regulation of NK cells in cancer protection. Trends Mol Med. (2016) 22:565–77. 10.1016/j.molmed.2016.05.007
33.
Palsson-McDermottEMO'NeillLA. The Warburg effect then and now: from cancer to inflammatory diseases. Bioessays. (2013) 35:965–73. 10.1002/bies.201300084
34.
PearceELPearceEJ. Metabolic pathways in immune cell activation and quiescence. Immunity. (2013) 38:633–43. 10.1016/j.immuni.2013.04.005
35.
MichalekRDGerrietsVAJacobsSRMacintyreANMacIverNJMasonEFet al. Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets. J Immunol. (2011) 186:3299–303. 10.4049/jimmunol.1003613
36.
DhupSDadhichRKPorporatoPESonveauxP. Multiple biological activities of lactic acid in cancer: influences on tumor growth, angiogenesis and metastasis. Curr Pharm Des. (2012) 18:1319–30. 10.2174/138161212799504902
37.
FallarinoFGrohmannUVaccaCBianchiROrabonaCSprecaAet al. T cell apoptosis by tryptophan catabolism. Cell Death Differ. (2002) 9:1069–77. 10.1038/sj.cdd.4401073
38.
O'DonnellJSMassiDTengMWLMandalaM. PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux. Semin Cancer Biol. (2018) 48:91–103. 10.1016/j.semcancer.2017.04.015
39.
FridmanWHPagesFSautes-FridmanCGalonJ. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. (2012) 12:298–306. 10.1038/nrc3245
40.
OkkenhaugK. Signaling by the phosphoinositide 3-kinase family in immune cells. Ann Rev Immunol. (2013) 31:675–704. 10.1146/annurev-immunol-032712-095946
41.
KimEHSureshM. Role of PI3K/Akt signaling in memory CD8 T cell differentiation. Front Immunol. (2013) 1:4–20. 10.3389/fimmu.2013.00020
42.
PengWChenJQLiuCMaluSCreasyCTetzlaffMTet al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov. (2016) 6:202–16. 10.1158/2159-8290.CD-15-0283
43.
Abu-EidRSamaraRNOzbunLAbdallaMYBerzofskyJAFriedmanKMet al. Selective inhibition of regulatory T cells by targeting the PI3K-Akt pathway. Cancer Immunol Res. (2014) 2:1080–9. 10.1158/2326-6066.CIR-14-0095
44.
van der WaartABvan de WeemNMMaasFKramerCSKesterMGFalkenburgJHet al. Inhibition of Akt signaling promotes the generation of superior tumor-reactive T cells for adoptive immunotherapy. Blood. (2014) 124:3490–500. 10.1182/blood-2014-05-578583
45.
LazarevicVGlimcherLhFau—LordGMLordGM. T-bet: a bridge between innate and adaptive immunity. Nat Rev Immunol. (2013) 13:777–89. 10.1038/nri3536
46.
OkkenhaugKTurnerMGoldMR. PI3K Signaling in B cell and T cell biology. Front Immunol. (2014) 5:557. 10.3389/fimmu.2014.00557
47.
KremmidiotisGBakerECrawfordJEyreHJNahmiasJCallenDF. Localization of human cadherin genes to chromosome regions exhibiting cancer-related loss of heterozygosity. Genomics. (1998) 49:467–71. 10.1006/geno.1998.5281
48.
WinklmeierAContreras-ShannonVArndtSMelleCBosserhoffAK. Cadherin-7 interacts with melanoma inhibitory activity protein and negatively modulates melanoma cell migration. Cancer Sci. (2009) 100:261–8. 10.1111/j.1349-7006.2008.01048.x
49.
MooreRChampevalDDenatLTanSSFaureFJulien-GrilleSet al. Involvement of cadherins 7 and 20 in mouse embryogenesis and melanocyte transformation. Oncogene. (2004) 23:6726–35. 10.1038/sj.onc.1207675
50.
LiGYuanLLiuDLiuJ. Upregulation of leucine zipper protein mRNA in hepatocellular carcinoma associated with poor prognosis.Technol Cancer Res Treat. (2016) 15:517–22. 10.1177/1533034615587432
51.
ChenXLiDWangNYangMLiaoAWangSet al. Bioinformatic analysis suggests that UGT2B15 activates the HippoYAP signaling pathway leading to the pathogenesis of gastric cancer. Oncol Rep. (2018) 40:1855–62. 10.3892/or.2018.6604
52.
HuDGSelthLATarulliGAMeechRWijayakumaraDChanawongAet al. Androgen and estrogen receptors in breast cancer coregulate human UDP-Glucuronosyltransferases 2B15 and 2B17. Cancer Res. (2016) 76:5881–93. 10.1158/0008-5472.CAN-15-3372
53.
GrosseLPaquetSCaronPFazliLRenniePSBelangerAet al. Androgen glucuronidation: an unexpected target for androgen deprivation therapy, with prognosis and diagnostic implications. Cancer Res. (2013) 73:6963–71. 10.1158/0008-5472.CAN-13-1462
Summary
Keywords
bladder urinary cancer, immunotherapy, tumor microenvironment, TCGA, bioinformatics
Citation
Cao J, Yang X, Li J, Wu H, Li P, Yao Z, Dong Z and Tian J (2020) Screening and Identifying Immune-Related Cells and Genes in the Tumor Microenvironment of Bladder Urothelial Carcinoma: Based on TCGA Database and Bioinformatics. Front. Oncol. 9:1533. doi: 10.3389/fonc.2019.01533
Received
24 September 2019
Accepted
19 December 2019
Published
15 January 2020
Volume
9 - 2019
Edited by
Woonyoung Choi, The Johns Hopkins Hospital, Johns Hopkins Medicine, United States
Reviewed by
Rasha Abu Eid, University of Aberdeen, United Kingdom; Daniele Baiz, University of Plymouth, United Kingdom
Updates
Copyright
© 2020 Cao, Yang, Li, Wu, Li, Yao, Dong and Tian.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Junqiang Tian ery_tianjq@lzu.edu.cn
This article was submitted to Genitourinary Oncology, a section of the journal Frontiers in Oncology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.